 |
The Journal of Neuroscience, February 23, 2005, 25(8):1904-1913; doi:10.1523/JNEUROSCI.4540-04.2005
 Previous Article | Next Article 
Neurobiology of Disease
Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
Belén G. Ramírez,1
Cristina Blázquez,2
Teresa Gómez del Pulgar,2
Manuel Guzmán,2 and
María L. de Ceballos1
1Neurodegeneration Group, Cajal Institute, Consejo Superior de Investigaciones Científicas, 28002 Madrid, Spain, and 2Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, 28040 Madrid, Spain
Alzheimer's disease (AD) is characterized by enhanced  -amyloid peptide (A) deposition along with glial activation in senile plaques, selective neuronal loss, and cognitive deficits. Cannabinoids are neuroprotective agents against excitotoxicity in vitro and acute brain damage in vivo. This background prompted us to study the localization, expression, and function of cannabinoid receptors in AD and the possible protective role of cannabinoids after A treatment, both in vivo and in vitro. Here, we show that senile plaques in AD patients express cannabinoid receptors CB1 and CB2, together with markers of microglial activation, and that CB1-positive neurons, present in high numbers in control cases, are greatly reduced in areas of microglial activation. In pharmacological experiments, we found that G-protein coupling and CB1 receptor protein expression are markedly decreased in AD brains. Additionally, in AD brains, protein nitration is increased, and, more specifically, CB1 and CB2 proteins show enhanced nitration. Intracerebroventricular administration of the synthetic cannabinoid WIN55,212-2 to rats prevent A-induced microglial activation, cognitive impairment, and loss of neuronal markers. Cannabinoids (HU-210, WIN55,212-2, and JWH-133) block A-induced activation of cultured microglial cells, as judged by mitochondrial activity, cell morphology, and tumor necrosis factor- release; these effects are independent of the antioxidant action of cannabinoid compounds and are also exerted by a CB2-selective agonist. Moreover, cannabinoids abrogate microglia-mediated neurotoxicity after A addition to rat cortical cocultures. Our results indicate that cannabinoid receptors are important in the pathology of AD and that cannabinoids succeed in preventing the neurodegenerative process occurring in the disease.
Key words: Alzheimer's disease; -amyloid; cannabinoids; microglia; neurotoxicity; neuroprotection
Received Sep 9, 2004;
revised December 28, 2004;
accepted December 30, 2004.
This article has been cited by other articles:
|
|
|
|
 
J. Palazuelos, T. Aguado, M. R. Pazos, B. Julien, C. Carrasco, E. Resel, O. Sagredo, C. Benito, J. Romero, I. Azcoitia, et al.
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Brain,
November 1, 2009;
132(11):
3152 - 3164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dirikoc, S. A. Priola, M. Marella, N. Zsurger, and J. Chabry
Nonpsychoactive Cannabidiol Prevents Prion Accumulation and Protects Neurons against Prion Toxicity
J. Neurosci.,
September 5, 2007;
27(36):
9537 - 9544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Xu, C. L. Cheng, M. Chen, A. Manivannan, L. Cabay, R. G. Pertwee, A. Coutts, and J. V. Forrester
Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis
J. Leukoc. Biol.,
September 1, 2007;
82(3):
532 - 541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Karanian, S. L. Karim, J. T. Wood, J. S. Williams, S. Lin, A. Makriyannis, and B. A. Bahr
Endocannabinoid Enhancement Protects against Kainic Acid-Induced Seizures and Associated Brain Damage
J. Pharmacol. Exp. Ther.,
September 1, 2007;
322(3):
1059 - 1066.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Esposito, T. Iuvone, C. Savani, C. Scuderi, D. De Filippis, M. Papa, V. Di Marzo, and L. Steardo
Opposing Control of Cannabinoid Receptor Stimulation on Amyloid-beta-Induced Reactive Gliosis: In Vitro and in Vivo Evidence
J. Pharmacol. Exp. Ther.,
September 1, 2007;
322(3):
1144 - 1152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-J. Tsai, Y.-C. Tsai, and C.-K. J. Shen
G-CSF rescues the memory impairment of animal models of Alzheimer's disease
J. Exp. Med.,
June 11, 2007;
204(6):
1273 - 1280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. D. Burns, K. Van Laere, S. Sanabria-Bohorquez, T. G. Hamill, G. Bormans, W.-s. Eng, R. Gibson, C. Ryan, B. Connolly, S. Patel, et al.
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor
PNAS,
June 5, 2007;
104(23):
9800 - 9805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Galve-Roperh, T. Aguado, J. Palazuelos, and M. Guzman
The Endocannabinoid System and Neurogenesis in Health and Disease
Neuroscientist,
April 1, 2007;
13(2):
109 - 114.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Benito, J. P. Romero, R. M. Tolon, D. Clemente, F. Docagne, C. J. Hillard, C. Guaza, and J. Romero
Cannabinoid CB1 and CB2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis
J. Neurosci.,
February 28, 2007;
27(9):
2396 - 2402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Masters and K. Beyreuther
Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A{beta} amyloid pathway
Brain,
November 1, 2006;
129(11):
2823 - 2839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Palazuelos, T. Aguado, A. Egia, R. Mechoulam, M. Guzman, and I. Galve-Roperh
Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation
FASEB J,
November 1, 2006;
20(13):
2405 - 2407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Pacher, S. Batkai, and G. Kunos
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pharmacol. Rev.,
September 1, 2006;
58(3):
389 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
